![Open Access](/resources/images/iconopenaccess.png)
Tertiary lymphoid structure and B‑cell‑related pathways: A potential target in tumor immunotherapy (Review)
- Authors:
- Meng Qin
- Ying Jin
- Ling-Ya Pan
-
Affiliations: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China - Published online on: October 18, 2021 https://doi.org/10.3892/ol.2021.13097
- Article Number: 836
-
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Weinstein AM and Storkus WJ: Therapeutic lymphoid organogenesis in the tumor microenvironment. Adv Cancer Res. 128:197–233. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Zhu G, Falahat R, Wang K, Mailloux A, Artzi N and Mulé JJ: Tumor-associated tertiary lymphoid structures: Gene-expression profiling and their bioengineering. Front Immunol. 8:7672017. View Article : Google Scholar : PubMed/NCBI |
|
Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C and Fridman WH: Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother. 63:991–997. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I and Dieu-Nosjean MC: Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 30:13–25. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Zhang Y, Gallastegui N and Rosenblatt JD: Regulatory B cells in anti-tumor immunity. Int Immunol. 27:521–530. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH and Dieu-Nosjean MC: Tertiary lymphoid structures in cancers: Prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 7:4072016. View Article : Google Scholar : PubMed/NCBI |
|
Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM and Karin M: Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 470:548–553. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Serafini P: Myeloid derived suppressor cells in physiological and pathological conditions: The good, the bad, and the ugly. Immunol Res. 57:172–184. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Khaled YS, Ammori BJ and Elkord E: Myeloid-derived suppressor cells in cancer: Recent progress and prospects. Immunol Cell Biol. 91:493–502. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Gadducci A and Guerrieri ME: Immune checkpoint inhibitors in gynecological cancers: Update of literature and perspectives of clinical research. Anticancer Res. 37:5955–5965. 2017.PubMed/NCBI |
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al: A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 24:994–1004. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, et al: Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. OncoImmunology. 6:e12574522016. View Article : Google Scholar : PubMed/NCBI |
|
Lee YY, Choi CH, Sung CO, Do IG, Hub SJ, Kim HJ, Kim TJ, Lee JW, Bae DS and Kim BG: Clinical significance of changes in peripheral lymphocyte count after surgery in early cervical cancer. Gynecol Oncol. 127:107–113. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, et al: High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 67:354–361. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Wartenberg M, Cibin S, Zlobec I, Vassella E, Eppenberger-Castori S, Terracciano L, Eichmann MD, Worni M, Gloor B, Perren A, et al: Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res. 24:4444–4454. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Nielsen JS and Nelson BH: Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology. 1:1623–1625. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Wang SS, Liu W, Ly D, Xu H, Qu L and Zhang L: Tumor-infiltrating B cells: Their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 16:6–18. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Lin L, Hu X, Zhang H and Hu H: Tertiary lymphoid organs in cancer immunology: Mechanisms and the new strategy for immunotherapy. Front Immunol. 10:13982019. View Article : Google Scholar : PubMed/NCBI |
|
Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H and Lenz HJ: B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev. 73:10–19. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Willard-Mack CL: Normal structure, function, and histology of lymph nodes. Toxicol Pathol. 34:409–424. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Mantovani A and Marchesi F: Tertiary lymphoid tissue in the tumor microenvironment: From its occurrence to immunotherapeutic implications. Int Rev Immunol. 34:123–133. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C and Fridman WH: Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35:571–580. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Ager A and May MJ: Understanding high endothelial venules: Lessons for cancer immunology. OncoImmunology. 4:e10087912015. View Article : Google Scholar : PubMed/NCBI |
|
Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean MC, Alifano M, Régnard JF, et al: Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71:5412–5422. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al: Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 577:561–565. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Tang H, Qiu X, Timmerman C and Fu YX: Targeting tertiary lymphoid structures for tumor immunotherapy. Methods Mol Biol. 1845:275–286. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Gu-Trantien C and Willard-Gallo K: Tumor-infiltrating follicular helper T cells: The new kids on the block. Oncoimmunology. 2:e260662013. View Article : Google Scholar : PubMed/NCBI |
|
Jing F and Choi EY: Potential of cells and cytokines/chemokines to regulate tertiary lymphoid structures in human diseases. Immune Netw. 16:271–280. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Nerviani A and Pitzalis C: Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol. 104:333–341. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, et al: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology. 7:e13788442017. View Article : Google Scholar : PubMed/NCBI |
|
Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, et al: Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78:1308–1320. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Kroeger DR, Milne K and Nelson BH: Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 22:3005–3015. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T and Shimada K: Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 112:1782–1790. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Bento DC, Jones E, Junaid S, Tull J, Williams GT, Godkin A, Ager A and Gallimore A: High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology. 4:e9743742015. View Article : Google Scholar : PubMed/NCBI |
|
Figenschau SL, Fismen S, Fenton KA, Fenton C and Mortensen ES: Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer. 15:1012015. View Article : Google Scholar : PubMed/NCBI |
|
Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, Vlachodimitropoulos D, Perez SA and Baxevanis CN: The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 68:1733–1745. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Jones E, Gallimore A and Ager A: Defining high endothelial venules and tertiary lymphoid structures in cancer. Methods Mol Biol. 1845:99–118. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Drayton DL, Liao S, Mounzer RH and Ruddle NH: Lymphoid organ development: From ontogeny to neogenesis. Nat Immunol. 7:344–353. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Song IH, Heo SH, Bang WS, Park HS, Park IA, Kim YA, Park SY, Roh J, Gong G and Lee HJ: Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res Treat. 49:399–407. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P and Girard JP: Human solid tumors contain high endothelial venules: Association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71:5678–5687. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T, Stein JV and Ludewig B: Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J Exp Med. 210:465–473. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S and Fava RA: Lymphotoxin-β receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity. 23:539–550. 2005. View Article : Google Scholar : PubMed/NCBI |
|
Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I and Girard J-P: High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J Immunol. 191:2001–2008. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Uchimura K and Rosen SD: Sulfated L-selectin ligands as a therapeutic target in chronic inflammation. Trends Immunol. 27:559–565. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Kobayashi M, Lee H, Schaffer L, Gilmartin TJ, Head SR, Takaishi S, Wang TC, Nakayama J and Fukuda M: A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by Helicobacter felis. J Histochem Cytochem. 55:263–274. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I and Girard JP: High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. OncoImmunology. 1:829–839. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, Cutting S, Ladell K, Wynn KK, Withers D, et al: T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 72:5473–5482. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Germain C, Gnjatic S and Dieu-Nosjean MC: Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol. 6:672015. View Article : Google Scholar : PubMed/NCBI |
|
Sautès-Fridman C, Petitprez F, Calderaro J and Fridman WH: Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 19:307–325. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Clement M, Guedj K, Andreata F, Morvan M, Bey L, Khallou-Laschet J, Gaston AT, Delbosc S, Alsac JM, Bruneval P, et al: Control of the T follicular helper-germinal center B-cell axis by CD8+ regulatory T cells limits atherosclerosis and tertiary lymphoid organ development. Circulation. 131:560–570. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, et al: B cells are associated with survival and immunotherapy response in sarcoma. Nature. 577:556–560. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Siliņa K, Rulle U, Kalniņa Z and Linē A: Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: A novel anti-cancer treatment avenue? Cancer Immunol Immunother. 63:643–662. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, et al: A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res. 7:784–796. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, Oh S, Sabzghabaei N, et al: Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 34:108–121. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, et al: CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. 2:22017. View Article : Google Scholar : PubMed/NCBI |
|
Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV, et al: CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat. 143:265–276. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Garg R, Blando JM, Perez CJ, Abba MC, Benavides F and Kazanietz MG: Protein kinase C epsilon cooperates with PTEN loss for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Rep. 19:375–388. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Pang MF, Georgoudaki AM, Lambut L, Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS, Nelson CM, et al: TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. Oncogene. 35:748–760. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ and Swartz MA: Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell. 11:526–538. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Zou Y, Chen Y, Wu X, Yuan R, Cai Z, He X, Fan X, Wang L, Wu X and Lan P: CCL21 as an independent favorable prognostic factor for stage III/IV colorectal cancer. Oncol Rep. 30:659–666. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Hill DG, Yu L, Gao H, Balic JJ, West A, Oshima H, McLeod L, Oshima M, Gallimore A, D'Costa K, et al: Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. Int J Cancer. 143:167–178. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Pimenta EM and Barnes BJ: Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: Potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelial-derived cancers. Cancers (Basel). 6:969–997. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Lee JM, Lee M-H, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, et al: Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration. Clin Cancer Res. 23:4556–4568. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Sperveslage J, Frank S, Heneweer C, Egberts J, Schniewind B, Buchholz M, Bergmann F, Giese N, Munding J, Hahn SA, et al: Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Int J Cancer. 131:E371–E381. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al: Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2:616–631. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TN, Andersen MH, thor Straten P, Reisfeld RA and Becker JC: Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother. 57:85–95. 2008. View Article : Google Scholar : PubMed/NCBI |
|
Johansson-Percival A, He B, Li ZJ, Kjellén A, Russell K, Li J, Larma I and Ganss R: De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol. 18:1207–1217. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X and Fu Y-X: Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 29:285–296. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Gantsev SK, Umezawa K, Islamgulov DV, Khusnutdinova EK, Ishmuratova RS, Frolova VY and Kzyrgalin SR: The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer. Biomed Pharmacother. 67:363–366. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Kim A, Heo SH, Kim YA, Gong G and Jin Lee H: An examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphoctytes. Am J Clin Pathol. 146:137–144. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Liu X, Tsang JYS, Hlaing T, Hu J, Ni YB, Chan SK, Cheung SY and Tse GM: Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers. Oncologist. 22:1316–1324. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, et al: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5:52019.PubMed/NCBI |
|
Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud W, Canon JL, Gombos A, Dalenc F, Delaloge S, et al: Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res. 21:652019. View Article : Google Scholar : PubMed/NCBI |
|
Freier CP, Kuhn C, Endres S, Mayr D, Friese K, Jeschke U and Anz D: FOXP3+ cells recruited by CCL22 into breast cancer correlates with less tumor nodal infiltration. Anticancer Res. 36:3139–3145. 2016.PubMed/NCBI |
|
Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, et al: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69:2000–2009. 2009. View Article : Google Scholar : PubMed/NCBI |
|
Pitzalis C, Jones GW, Bombardieri M and Jones SA: Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 14:447–462. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 26:4410–4417. 2008. View Article : Google Scholar : PubMed/NCBI |
|
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al: Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74:705–715. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Luketich JD and Schuchert MJ: Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 171:1–5. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Kim A, Lee SJ, Ahn J, Park WY, Shin DH, Lee CH, Kwon H, Jeong YJ, Ahn HY, I H, et al: The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma. PLoS One. 14:e02244302019. View Article : Google Scholar : PubMed/NCBI |
|
Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, et al: A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality. Oncoimmunology. 4:e10519222015. View Article : Google Scholar : PubMed/NCBI |
|
de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautès-Fridman C and Dieu-Nosjean MC: Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71:6391–6399. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pagès F, Tartour E and Sautès-Fridman C: Immune infiltration in human cancer: Prognostic significance and disease control. Curr Top Microbiol Immunol. 344:1–24. 2011.PubMed/NCBI |
|
Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, et al: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 15:6412–6420. 2009. View Article : Google Scholar : PubMed/NCBI |
|
McMullen TP, Lai R, Dabbagh L, Wallace TM and de Gara CJ: Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp Immunol. 161:81–88. 2010.PubMed/NCBI |
|
Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin Cancer Res. 19:4079–4091. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, et al: Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunol Immunother. 68:109–120. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Muniz LR, Pacer ME, Lira SA and Furtado GC: A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J Immunol. 187:828–834. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L and Li C: Tumour-infiltrating inflammation and prognosis in colorectal cancer: Systematic review and meta-analysis. Br J Cancer. 110:1595–1605. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S, Jensen-Jarolim E, Grünberger T, et al: B cells and ectopic follicular structures: Novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One. 9:e990082014. View Article : Google Scholar : PubMed/NCBI |
|
Schweiger T, Berghoff AS, Glogner C, Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W and Hoetzenecker K: Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp Metastasis. 33:727–739. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H and van Hall T: HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci USA. 108:10656–10661. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, et al: Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 6:1392018. View Article : Google Scholar : PubMed/NCBI |
|
Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I and Tímár J: Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 56:1459–1469. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG and van Baren N: Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72:3997–4007. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS and Mulé JJ: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunotherapy? Sci Rep. 2:7652012. View Article : Google Scholar : PubMed/NCBI |
|
Shields JD, Kourtis IC, Tomei AA, Roberts JM and Swartz MA: Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 328:749–752. 2010. View Article : Google Scholar : PubMed/NCBI |